ESMO WCGIC 2021 | Impact of prior systemic therapy on PFS patients enrolled in FIGHT-202

Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, presents the findings of a post-hoc analysis of prior systemic therapy response on progression-free survival (PFS) patients enrolled in FIGHT-202 (NCT02924376), a Phase II study evaluating the efficacy and safety of pemigatinib in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma who have failed previous therapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.